NEWAMSTERDAM PHARMA CO NV(NAMS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NAMS NEWAMSTERDAM PHARMA CO NV

未开盘 09-30 16:00:00 EDT

24.32

+0.51

+2.14%

盘后24.60

+0.28+1.15%

19:30 EDT

最高25.12	最低23.96	成交量227.04万
今开24.00	昨收23.81	日振幅4.87%
总市值29.07亿	流通市值22.07亿	总股本1.20亿
成交额5,596万	换手率2.50%	流通股本9,076万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NAMS","market":"US","secType":"STK","nameCN":"NEWAMSTERDAM PHARMA CO NV","latestPrice":24.32,"timestamp":1790798400000,"preClose":23.81,"halted":0,"volume":2270418,"hourTrading":{"tag":"盘后","latestPrice":24.6,"preClose":24.32,"latestTime":"19:30 EDT","volume":23891,"amount":581098.2,"timestamp":1790811002350,"change":0.28,"changeRate":0.011513,"amplitude":0.011513},"delay":0,"changeRate":0.021419571608567896,"floatShares":90756826,"shares":119537169,"eps":-2.144229,"marketStatus":"未开盘","change":0.51,"latestTime":"09-30 16:00:00 EDT","open":24,"high":25.12,"low":23.96,"amount":55959600.918024,"amplitude":0.048719,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.144229,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":23.81,"preHourTrading":{"tag":"盘前","latestPrice":24.29,"preClose":23.81,"latestTime":"09:27 EDT","volume":801,"amount":19360.309374,"timestamp":1790774860037,"change":0.48,"changeRate":0.02016,"amplitude":0.021},"postHourTrading":{"tag":"盘后","latestPrice":24.6,"preClose":24.32,"latestTime":"19:30 EDT","volume":23891,"amount":581098.2,"timestamp":1790811002350,"change":0.28,"changeRate":0.011513,"amplitude":0.011513},"volumeRatio":1.358245,"impliedVol":0.7321,"impliedVolPercentile":0.4861},"requestUrl":"/m/hq/s/NAMS","defaultTab":"news","newsList":[{"id":"1156519674","title":"Menarini集团与NewAmsterdam Pharma联合宣布：欧盟委员会正式批准Ubeslo与Evlarco上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1156519674","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156519674?lang=zh_cn&edition=full","pubTime":"2026-09-22 00:49","pubTimestamp":1790009373,"startTime":"0","endTime":"0","summary":"9月21日，路透社消息——NewAmsterdam Pharma Company N.V.今日披露重大进展。Menarini集团与NewAmsterdam Pharma共同宣布，其旗下两款创新药物已获得欧盟委员会的正式上市批准。具体而言，Ubeslo与Evlarco双双通过审评，标志着这一治疗领域的重要突破。据悉，此次获批将为欧洲患者带来新的治疗选择。NewAmsterdam Pharma专注于心血管代谢疾病领域，此次欧盟层面的绿灯放行，不仅验证了其研发管线的临床价值，也为公司进一步拓展全球市场奠定了坚实基础。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115930814","title":"纽阿姆斯特丹制药披露纳斯达克上市规则5635(c)(4)项下的激励性授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1115930814","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115930814?lang=zh_cn&edition=full","pubTime":"2026-09-04 05:47","pubTimestamp":1788472069,"startTime":"0","endTime":"0","summary":"9月3日（路透社）——纽阿姆斯特丹制药公司（NewAmsterdam Pharma Company N.V.）于今日正式对外宣布，公司已依据纳斯达克上市规则第5635(c)(4)条款，完成了一系列激励性股票授予的相关报告事宜。\n此项公告标志着公司在其股权激励计划框架下，进一步落实了对关键人才的吸引与留任策略。通过此类授予，公司旨在将管理层及核心员工的利益与股东价值创造更紧密地绑定在一起。\n上述授予行为严格遵循了纳斯达克关于此类激励性补偿的特定披露要求，体现了公司在公司治理与合规运营方面的承诺。\n（本报道基于路透社投资者简报整理）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194959212","title":"NewAmsterdam Pharma公司N.V.：Obicetrapib及Obicetrapib/依折麦布获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1194959212","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194959212?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:32","pubTimestamp":1785933128,"startTime":"0","endTime":"0","summary":"8月5日（路透社）——NewAmsterdam Pharma公司N.V.今日宣布，其两款药物Obicetrapib及Obicetrapib/依折麦布（Obicetrapib/Ezetimibe）已获得欧洲药品管理局（EMA）人用药品委员会（CHMP）的积极意见。这一里程碑式的进展，标志着该公司的研发管线迈出了关键一步。\n此外，公司透露，PREVAIL研究的中期分析计划于2026年第四季度进行，预计相关结果将在2027年第一季度公布。与此同时，RUBENS三期临床试验的顶线数据有望在2026年年底前出炉。这一连串的预期时间点，为投资者勾勒出清晰的研发进展路线图。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518271343","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘股价大跌5.13%报22.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271343","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518271343?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:55","pubTimestamp":1741618539,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时55分，Newamsterdam Pharma Company N.V.股票出现波动，股价急速下跌5.13%。截至发稿，该股报22.58美元/股，成交量30.715万股，换手率0.28%，振幅5.21%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.27%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225539a26a44bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225539a26a44bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517926192","title":"Newamsterdam Pharma Company N.V.盘中异动 股价大涨5.12%报22.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517926192","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517926192?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:06","pubTimestamp":1741205206,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时06分，Newamsterdam Pharma Company N.V.股票出现波动，股价急速上涨5.12%。截至发稿，该股报22.60美元/股，成交量62.7351万股，换手率0.57%，振幅7.44%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为1.94%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306040647963b255d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306040647963b255d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516002608","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘急速拉升5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516002608","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516002608?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:10","pubTimestamp":1741101003,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时10分，Newamsterdam Pharma Company N.V.股票出现波动，股价大幅上涨5.33%。截至发稿，该股报21.35美元/股，成交量36.0325万股，换手率0.33%，振幅5.40%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.59%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231004abe7fb52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231004abe7fb52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385613","title":"Newamsterdam Pharma Company N.V.盘中异动 大幅拉升5.07%报20.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385613","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385613?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:40","pubTimestamp":1740667228,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时40分，Newamsterdam Pharma Company N.V.股票出现异动，股价快速上涨5.07%。截至发稿，该股报20.71美元/股，成交量2.2103万股，换手率0.02%，振幅3.50%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.69%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224029abdf70f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224029abdf70f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514785615","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514785615","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514785615?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:43","pubTimestamp":1740581001,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时43分，Newamsterdam Pharma Company N.V.股票出现波动，股价大幅拉升5.26%。截至发稿，该股报18.82美元/股，成交量2.3269万股，换手率0.02%，振幅3.54%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为0.48%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262243219893ad41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262243219893ad41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137434239","title":"NewAmsterdam制药公司2024财年销售额达4560万美元，超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1137434239","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137434239?lang=zh_cn&edition=full","pubTime":"2025-02-26 21:14","pubTimestamp":1740575644,"startTime":"0","endTime":"0","summary":"NewAmsterdam制药公司公布了2024财年全年财务业绩。现金状况：截至2024年12月31日，新阿姆斯特丹的现金及现金等价物为7.717亿美元，另有6250万美元的有价证券，而2023年12月31日的现金及现金等价物为3.405亿美元。收入：截至2024年12月31日，NewAmsterdam全年收入为4560万美元，而2023年同期为1410万美元。销售、管理费用：2024年销售、管理费用为7040万美元，而2023年为3760万美元。净亏损：2024年净亏损为2.416亿美元，而2023年净亏损为1.769亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NewAmsterdam制药公司2024财年销售额达4560万美元，超出预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514705918","title":"Newamsterdam Pharma Company N.V.盘中异动 急速下跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514705918","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514705918?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:51","pubTimestamp":1740430278,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时51分，Newamsterdam Pharma Company N.V.股票出现异动，股价大幅下挫5.12%。截至发稿，该股报17.62美元/股，成交量55.6253万股，换手率0.52%，振幅5.92%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为0.27%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225045118a2526385&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225045118a2526385&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510689132","title":"Newamsterdam Pharma Company N.V.盘中异动 大幅下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510689132","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510689132?lang=zh_cn&edition=full","pubTime":"2025-02-11 02:26","pubTimestamp":1739212014,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日02时26分，Newamsterdam Pharma Company N.V.股票出现波动，股价急速下挫5.05%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为0.26%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211022654a240d296&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211022654a240d296&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509277779","title":"Newamsterdam Pharma Company N.V.盘中异动 股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509277779","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509277779?lang=zh_cn&edition=full","pubTime":"2025-02-08 04:52","pubTimestamp":1738961557,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日04时52分，Newamsterdam Pharma Company N.V.股票出现波动，股价快速下挫5.07%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为0.90%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208045237a23d71da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208045237a23d71da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509277747","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘急速下跌5.37%报19.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509277747","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509277747?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:35","pubTimestamp":1738852518,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时35分，Newamsterdam Pharma Company N.V.股票出现波动，股价快速下跌5.37%。截至发稿，该股报19.92美元/股，成交量5.4961万股，换手率0.05%，振幅8.43%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为0.19%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223518a23bcf45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223518a23bcf45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507964330","title":"Newamsterdam Pharma Company N.V.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507964330","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507964330?lang=zh_cn&edition=full","pubTime":"2025-01-31 23:26","pubTimestamp":1738337199,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日23时26分，Newamsterdam Pharma Company N.V.股票出现波动，股价快速上涨5.01%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为1.36%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312326409614f1ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312326409614f1ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507137674","title":"Newamsterdam Pharma Company N.V.盘中异动 股价大涨5.20%报21.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507137674","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507137674?lang=zh_cn&edition=full","pubTime":"2025-01-31 02:51","pubTimestamp":1738263078,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日02时51分，Newamsterdam Pharma Company N.V.股票出现波动，股价急速上涨5.20%。截至发稿，该股报21.86美元/股，成交量50.9734万股，换手率0.48%，振幅6.54%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.37%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131025118abbd7870&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131025118abbd7870&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507542660","title":"Newamsterdam Pharma Company N.V.盘中异动 急速下跌5.00%报21.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507542660","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507542660?lang=zh_cn&edition=full","pubTime":"2025-01-29 02:43","pubTimestamp":1738089803,"startTime":"0","endTime":"0","summary":"北京时间2025年01月29日02时43分，Newamsterdam Pharma Company N.V.股票出现异动，股价急速下跌5.00%。截至发稿，该股报21.48美元/股，成交量10.5795万股，换手率0.10%，振幅4.51%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.13%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250129024323abbb975f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250129024323abbb975f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506585831","title":"Newamsterdam Pharma Company N.V.盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506585831","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506585831?lang=zh_cn&edition=full","pubTime":"2025-01-28 02:15","pubTimestamp":1738001753,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日02时15分，Newamsterdam Pharma Company N.V.股票出现异动，股价大幅跳水5.08%。截至发稿，该股报22.40美元/股，成交量99.3574万股，换手率0.93%，振幅5.68%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.73%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280215539874d17f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280215539874d17f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503919076","title":"Newamsterdam Pharma Company N.V.盘中异动 急速跳水5.41%报22.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503919076","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503919076?lang=zh_cn&edition=full","pubTime":"2025-01-16 23:42","pubTimestamp":1737042165,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日23时42分，Newamsterdam Pharma Company N.V.股票出现波动，股价大幅下跌5.41%。截至发稿，该股报22.70美元/股，成交量10.5007万股，换手率0.10%，振幅4.90%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为0.68%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116234246abad60b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116234246abad60b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492153744","title":"Newamsterdam Pharma Company N.V.盘中异动 下午盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492153744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492153744?lang=zh_cn&edition=full","pubTime":"2024-12-19 04:05","pubTimestamp":1734552311,"startTime":"0","endTime":"0","summary":"北京时间2024年12月19日04时05分，Newamsterdam Pharma Company N.V.股票出现异动，股价快速跳水5.07%。截至发稿，该股报25.26美元/股，成交量63.2441万股，换手率0.59%，振幅5.45%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为2.02%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219040511a1f94c86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219040511a1f94c86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492993393","title":"Newamsterdam Pharma Company N.V.盘中异动 急速上涨5.18%报25.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492993393","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492993393?lang=zh_cn&edition=full","pubTime":"2024-12-18 01:22","pubTimestamp":1734456158,"startTime":"0","endTime":"0","summary":"北京时间2024年12月18日01时22分，Newamsterdam Pharma Company N.V.股票出现异动，股价急速拉升5.18%。截至发稿，该股报25.99美元/股，成交量64.2548万股，换手率0.60%，振幅6.03%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.85%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121801223895ea34e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121801223895ea34e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.newamsterdampharma.com","stockEarnings":[{"period":"1week","weight":0.021},{"period":"1month","weight":-0.0807},{"period":"3month","weight":-0.323},{"period":"6month","weight":-0.2783},{"period":"1year","weight":-0.1348},{"period":"ytd","weight":-0.3213}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0247},{"period":"6month","weight":0.1652},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.1207}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"NewAmsterdam Pharma Company N.V.于2019年10月17日以NewAmsterdam Pharma B.V.的名义根据荷兰法律成立为一家私人有限责任公司。NewAmsterdam Pharma于2021年10月更名为NewAmsterdam Pharma Holding B.V.。他们是一家临床阶段的生物制药公司，为心血管疾病（CVD）高危患者开发口服非他汀类药物，这些患者的低密度脂蛋白胆固醇（LDL-C或LDL）残留升高，而现有疗法对这些患者不够有效或耐受良好。作为他汀类药物的辅助药物，一种有效的、具有成本效益的和方便的低密度脂蛋白降低疗法存在着巨大的未满足需求。他汀类药物是目前高胆固醇高危CVD患者的标准护理。他们的主要候选产品obicetrapib是一种下一代口服低剂量胆固醇酯转移蛋白（CETP）抑制剂，目前正在进行四项3期和2b期临床试验，作为单一疗法和依折麦布联合疗法，用于降低LDL-C和预防主要心血管不良事件（“MACE”）。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.163842},{"month":2,"riseRate":0.4,"avgChangeRate":0.036652},{"month":3,"riseRate":0.5,"avgChangeRate":-0.017313},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.029307},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.010913},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.017361},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.019958},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.021568},{"month":9,"riseRate":0.666667,"avgChangeRate":0.008147},{"month":10,"riseRate":0.6,"avgChangeRate":0.067332},{"month":11,"riseRate":0.6,"avgChangeRate":0.02866},{"month":12,"riseRate":0.6,"avgChangeRate":0.126441}],"exchange":"NASDAQ","name":"NEWAMSTERDAM PHARMA CO NV","nameEN":"NEWAMSTERDAM PHARMA CO NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEWAMSTERDAM PHARMA CO NV(NAMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NEWAMSTERDAM PHARMA CO NV(NAMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NEWAMSTERDAM PHARMA CO NV,NAMS,NEWAMSTERDAM PHARMA CO NV股票,NEWAMSTERDAM PHARMA CO NV股票老虎,NEWAMSTERDAM PHARMA CO NV股票老虎国际,NEWAMSTERDAM PHARMA CO NV行情,NEWAMSTERDAM PHARMA CO NV股票行情,NEWAMSTERDAM PHARMA CO NV股价,NEWAMSTERDAM PHARMA CO NV股市,NEWAMSTERDAM PHARMA CO NV股票价格,NEWAMSTERDAM PHARMA CO NV股票交易,NEWAMSTERDAM PHARMA CO NV股票购买,NEWAMSTERDAM PHARMA CO NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEWAMSTERDAM PHARMA CO NV(NAMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NEWAMSTERDAM PHARMA CO NV(NAMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}